DNA微阵列市场－全球产业规模、份额、趋势、机会及预测（按类型、应用、最终用途、地区和竞争格局划分，2021-2031年）

全球DNA微阵列市场预计将从2025年的24.3亿美元成长到2031年的40.6亿美元，复合年增长率为8.93%。

这些分析设备能够将微小的DNA片段固定在固体相基质上，在量化基因表现水平和同时对不同基因组区域进行基因分型方面发挥着至关重要的作用。市场成长的主要驱动力是癌症和遗传疾病发生率的上升，这导致个人化医疗和药物研发领域对高通量诊断仪器的需求激增。生命科学领域的大规模资本注入进一步推动了这一成长。根据美国药品研究与製造商协会（PhRMA）预测，其成员公司将在2024年投入约1,010亿美元用于研发，为基因组技术的应用奠定了坚实的资金基础。

儘管微阵列技术取得了这些进展，但它仍面临着一个重大挑战：来自次世代定序（NGS）的激烈竞争。由于NGS平台具有更高的灵敏度，并且能够识别基于晶片的方法难以检测到的新型基因变异，研究人员正逐渐将选择转向定序解决方案。这种技术转变对微阵列技术的持续应用构成了重大威胁，尤其是在需要全面基因组发现能力的高端研究领域。

市场驱动因素

遗传性疾病和癌症的日益普遍是全球DNA微阵列市场的主要驱动力，因为这些工具对于高通量基因表现分析和拷贝数变异分析至关重要。临床医生高度依赖微阵列来识别与复杂病理相关的生物标记物，而癌症疾病负担的不断加重进一步凸显了这种需求。根据美国癌症协会于2025年1月发布的《2025年癌症事实与数据》报告，预计仅在美国就将新增2,041,910例癌症病例。这一成长趋势要求使用可靠的诊断平台，并确保即使在其他定序方法兴起的情况下，人们仍将继续依赖基于微阵列的技术。

此外，微阵列技术在药物基因组学和药物发现领域的应用日益广泛，简化了毒性筛检和目标分子识别流程，也显着推动了市场成长。製药公司正利用这些平台追踪基因表现对潜在疗法的反应变化，加速个人化医疗的研发。这一蓬勃发展的产业也体现在主要企业的财务表现中。安捷伦科技公司于2025年2月发布的「2025财年第一季财务报告」预测，生命科学和诊断市场领域的销售额将达到6.47亿美元。该产业的庞大规模进一步凸显了这一投资趋势。据Illumina公司称，2025年营收将达43亿美元，高于2024年全年营收，显示支持微阵列市场的基因组技术将持续获得资金流入。

市场挑战

全球DNA微阵列市场成长的主要障碍是来自次世代定序（NGS）技术的激烈竞争。儘管微阵列在基因表现检测方面有着悠久的成功历史，但NGS平台具有显着的技术优势，包括更高的灵敏度以及发现基于微阵列方法难以检测到的新型基因突变的能力。这种功能能够实现更全面的基因组分析，并在复杂的诊断应用和高端研究中变得日益重要。因此，随着研究人员将资料深度置于传统微阵列的成本优势之上，实验室对定序的偏好发生了显着转变。

大量资金涌入製药创新领域，进一步推动了定序的普及，而精准性在製药创新领域至关重要。根据欧洲製药工业协会联合会（EFPIA）预测，到2024年，以研发为基础的製药业将在欧洲的研发领域投入约550亿欧元。如此庞大的投资凸显了市场格局的趋势：优先采用最先进的诊断工具以优化研究成果。随着越来越多的资金投入到能够提供更深入基因组资讯以用于个人化医疗和药物研发的技术中，DNA微阵列的市场份额和长期发展正受到新一代定序（NGS）日益增长的主导地位的直接威胁。

市场趋势

农业和环境基因组学应用范围的不断扩大，正使其市场超越传统的人类诊断领域。研究人员越来越多地利用高通量晶片基因分型技术，在畜牧改良和作物育种计划中进行标记辅助选择。这一转变的驱动力源于永续粮食生产的迫切需求以及快速识别农业环境中病原体的需求，而微阵列技术为筛检多样化的基因组提供了一种经济高效的解决方案。这些创新正得到资金的大力支持。根据美国国家食品与农业研究所（NIFA）于2024年7月发布的《NIFA最新动态》，该研究所宣布将投资800万美元，透过16项津贴支持农业植物生理学研究，直接促进该领域先进基因组工具的应用。

同时，人工智慧（AI）与生物资讯学流程的融合正在改变复杂微阵列资料的解读方式。随着阵列密度的增加，产生的数据量往往超出标准统计方法的承受能力，因此需要藉助人工智慧演算法进行自动化影像分析、精确探针设计和准确的基因表现分析。这种融合显着提高了基因分型的速度，并加速了广泛的基因组数据与表型特征之间的相关性分析，使阵列技术在复杂研究中更具实用性。计算医学领域估值的不断攀升也印证了这种融合的商业性潜力。在2025年1月举行的摩根大通医疗保健大会上，英伟达预测其医疗保健和生命科学部门到2025年将创造10亿美元的经常性收入，凸显了推动人工智慧驱动的基因组分析的大量资金流入。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球DNA微阵列市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依类型（互补DNA微阵列、寡核苷酸DNA微阵列、其他）
  • 依应用领域（基因表现分析、基因型分析等）
  • 按最终用户（製药和生物技术公司、诊断中心、医院和诊所、学术研究机构等）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美DNA微阵列市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲DNA微阵列市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区DNA微阵列市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东与非洲DNA微阵列市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲DNA微阵列市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球DNA微阵列市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Thermo Fisher Scientific, Inc.
• QIAGEN NV
• Illumina, Inc.
• F. Hoffmann-La Roche Ltd.
• Agilent Technologies, Inc.
• Merck KGaA
• bioMerieux SA
• PerkinElmer, Inc.
• Applied Micro Arrays Ltd.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global DNA Microarray Market is anticipated to expand from USD 2.43 Billion in 2025 to USD 4.06 Billion by 2031, reflecting a CAGR of 8.93%. These analytical devices, characterized by microscopic DNA spots affixed to a solid matrix, are essential for quantifying gene expression levels or genotyping various genomic regions simultaneously. The market's upward trajectory is largely fueled by the increasing incidence of cancer and genetic disorders, which creates a critical need for high-throughput diagnostic instruments in personalized medicine and drug discovery. This growth is bolstered by substantial capital infusion into life sciences innovation; according to the Pharmaceutical Research and Manufacturers of America, member companies invested nearly $101 billion in research and development in 2024, fostering a robust financial landscape for the implementation of genomic technologies.

Despite these advancements, the market encounters a formidable obstacle in the form of intense competition from Next-Generation Sequencing (NGS). NGS platforms provide enhanced sensitivity and the capacity to identify novel genetic variants that are often undetectable by array-based techniques, leading to a gradual migration of researcher preference toward sequencing solutions. This technological shift represents a significant threat to the sustained adoption of microarrays, especially within high-end research segments that demand exhaustive genomic discovery capabilities.

Market Driver

The escalating prevalence of genetic disorders and cancer serves as a primary catalyst for the Global DNA Microarray Market, rendering these tools essential for high-throughput gene expression profiling and the analysis of copy number variations. Clinicians depend heavily on microarrays to isolate biomarkers linked to complex pathologies, a need highlighted by the rising burden of oncological diseases. According to the American Cancer Society, January 2025, in the 'Cancer Facts & Figures 2025' report, it was projected that 2,041,910 new cancer cases would be diagnosed in the United States alone. This growing incidence mandates the use of reliable diagnostic platforms, ensuring continued reliance on array-based technologies even amidst the rise of alternative sequencing methods.

Moreover, market growth is significantly strengthened by the broadening utilization of microarrays in pharmacogenomics and drug discovery, where they streamline toxicity screening and target identification. Pharmaceutical entities employ these platforms to track gene expression shifts in response to potential therapeutics, thereby expediting the creation of personalized medicines. The vitality of this sector is reflected in the financial results of major industry participants; according to Agilent Technologies, February 2025, in the 'First-Quarter Fiscal Year 2025 Financial Results', the Life Sciences and Diagnostics Markets Group achieved revenue of $647 million. This investment trend is further emphasized by the industry's sheer scale; according to Illumina, in 2025, the company reported full-year 2024 revenue of $4.3 billion, demonstrating the persistent capital flow into genomic technologies that supports the microarray market.

Market Challenge

A major impediment to the Global DNA Microarray Market is the fierce competition presented by Next-Generation Sequencing (NGS) technologies. Although microarrays have a long-standing reputation for measuring gene expression, NGS platforms offer distinct technical benefits, including superior sensitivity and the capacity to uncover novel genetic variants that array-based approaches frequently fail to detect. This functionality facilitates a more exhaustive genomic analysis, which is becoming increasingly vital for complex diagnostic applications and high-end research. Consequently, there is a noticeable shift in laboratory preference toward sequencing, as researchers prioritize data depth over the cost advantages historically linked to microarrays.

This transition toward sequencing is further accelerated by significant financial resources dedicated to pharmaceutical innovation, a field where precision is essential. According to the European Federation of Pharmaceutical Industries and Associations, in 2024, the research-based pharmaceutical industry invested an estimated €55,000 million in R&D in Europe. Such massive investment highlights a market landscape that privileges the adoption of the most sophisticated diagnostic tools available to optimize research results. As funding increasingly targets technologies capable of providing deeper genomic insights for personalized medicine and drug discovery, the market share and long-term expansion of DNA microarrays are directly challenged by the growing dominance of NGS.

Market Trends

The Expansion of Applications in Agricultural and Environmental Genomics is extending the market's reach beyond its conventional focus on human diagnostics. Increasingly, researchers are deploying high-throughput array-based genotyping for marker-assisted selection within livestock improvement and crop breeding initiatives. This shift is motivated by the urgent requirement for sustainable food production and the swift identification of pathogens in agricultural environments, where microarrays provide a cost-efficient solution for screening varied genomes. Financial backing is actively accelerating these innovations; according to the National Institute of Food and Agriculture, July 2024, in the 'NIFA Update', the agency announced an investment of $8 million across 16 awards to support research in the physiology of agricultural plants, directly encouraging the use of advanced genomic tools in this sector.

Concurrently, the Integration of Artificial Intelligence in Bioinformatics Pipelines is transforming the interpretation of complex microarray data. As the density of arrays grows, the massive volume of data produced often exceeds the limits of standard statistical techniques, requiring AI algorithms for automated image analysis, precise probe design, and accurate gene expression profiling. This incorporation drastically improves the speed of genotype calling and hastens the correlation of extensive genomic data with phenotypic traits, thereby making array technology more viable for intricate studies. The commercial strength of this convergence is illustrated by the rising valuation of computational healthcare; according to NVIDIA, January 2025, in a presentation at the 'J.P. Morgan Healthcare Conference', the company projected that its healthcare and life sciences vertical would generate $1 billion in recurring revenue by 2025, underscoring the substantial capital inflow driving AI-powered genomic analysis.

Key Market Players

• Thermo Fisher Scientific, Inc.
• QIAGEN NV
• Illumina, Inc.
• F. Hoffmann-La Roche Ltd.
• Agilent Technologies, Inc.
• Merck KGaA
• bioMerieux S.A.
• PerkinElmer, Inc.
• Applied Micro Arrays Ltd.

Report Scope

In this report, the Global DNA Microarray Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

DNA Microarray Market, By Type

• Complementary DNA Microarrays
• Oligonucleotide DNA Microarrays
• Others

DNA Microarray Market, By Application

• Gene Expression Analysis
• Genotyping
• Others

DNA Microarray Market, By End Use

• Pharmaceutical and Biotechnology Companies
• Diagnostic Centers
• Hospitals and Clinics
• Academic and Research Institute
• Others

DNA Microarray Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global DNA Microarray Market.

Available Customizations:

Global DNA Microarray Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global DNA Microarray Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Complementary DNA Microarrays, Oligonucleotide DNA Microarrays, Others)
  • 5.2.2. By Application (Gene Expression Analysis, Genotyping, Others)
  • 5.2.3. By End Use (Pharmaceutical and Biotechnology Companies, Diagnostic Centers, Hospitals and Clinics, Academic and Research Institute, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America DNA Microarray Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By End Use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States DNA Microarray Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End Use
  • 6.3.2. Canada DNA Microarray Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End Use
  • 6.3.3. Mexico DNA Microarray Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End Use

7. Europe DNA Microarray Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By End Use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany DNA Microarray Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End Use
  • 7.3.2. France DNA Microarray Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End Use
  • 7.3.3. United Kingdom DNA Microarray Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End Use
  • 7.3.4. Italy DNA Microarray Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End Use
  • 7.3.5. Spain DNA Microarray Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End Use

8. Asia Pacific DNA Microarray Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End Use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China DNA Microarray Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End Use
  • 8.3.2. India DNA Microarray Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End Use
  • 8.3.3. Japan DNA Microarray Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End Use
  • 8.3.4. South Korea DNA Microarray Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End Use
  • 8.3.5. Australia DNA Microarray Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End Use

9. Middle East & Africa DNA Microarray Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By End Use
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia DNA Microarray Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End Use
  • 9.3.2. UAE DNA Microarray Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End Use
  • 9.3.3. South Africa DNA Microarray Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End Use

10. South America DNA Microarray Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By End Use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil DNA Microarray Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End Use
  • 10.3.2. Colombia DNA Microarray Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End Use
  • 10.3.3. Argentina DNA Microarray Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global DNA Microarray Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. QIAGEN NV
• 15.3. Illumina, Inc.
• 15.4. F. Hoffmann-La Roche Ltd.
• 15.5. Agilent Technologies, Inc.
• 15.6. Merck KGaA
• 15.7. bioMerieux S.A.
• 15.8. PerkinElmer, Inc.
• 15.9. Applied Micro Arrays Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer